EMERGENT BIOSOLUTIONS INC. Total Liabilities
EMERGENT BIOSOLUTIONS INC. (EBS) had Total Liabilities of $775.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $775.40M.
- 2026-03-31: Liabilities $797.30M.
- 2025-12-31: Liabilities $796.00M.
- 2025-09-30: Liabilities $878.50M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $775.40M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $797.30M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $796.00M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $878.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $880.90M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $873.40M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $906.90M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $969.40M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.13B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $1.14B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $1.17B 10-K · filed 2025-03-04 | |
| 2023-09-30 | $1.20B 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $1.22B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.75B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $1.78B 10-K · filed 2024-03-08 | $1.78B 10-K · filed 2023-03-01 |
| 2022-09-30 | $1.46B 10-Q · filed 2023-12-11 | $1.46B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.22B 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $1.21B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $1.35B 10-K/A · filed 2023-12-11 | $1.34B 10-K · filed 2022-02-25 |
| 2021-09-30 | $1.34B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.37B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $1.38B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $1.44B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $1.36B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $1.27B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $1.20B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $1.24B 10-K · filed 2021-02-19 | |
| 2019-09-30 | $1.30B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.33B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $1.17B 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $1.22B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $206.97M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $200.54M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $187.19M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $157.90M 10-K · filed 2019-02-22 | $157.86M 10-K · filed 2018-02-23 |
| 2017-09-30 | $360.49M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $349.88M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $341.22M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $373.91M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $384.40M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $383.79M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $368.92M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $377.47M 10-K · filed 2017-02-28 | $383.57M 10-K · filed 2016-02-29 |
| 2015-09-30 | $371.24M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $381.07M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $379.97M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $385.49M 10-K · filed 2016-02-29 | $392.06M 10-K · filed 2015-03-09 |
| 2014-09-30 | $356.15M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $349.48M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $345.76M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $137.47M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $128.61M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $106.53M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $102.58M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | $122.10M 10-K · filed 2014-03-10 | |
| 2012-09-30 | $111.61M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $104.62M 10-Q · filed 2012-08-03 | |
| 2012-03-31 | $102.59M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $130.14M 10-K · filed 2013-03-08 | |
| 2011-09-30 | $128.46M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $112.75M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $126.76M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |